SBIR/STTR Research Award
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
Award amount
$599,925Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R1JMHFESEKD5
- Solicitation number
- PHS-2023-1
- Topic code
- 116
Research abstract
The contractor will generate analogues of signal modifiers and co-formulate them with monophosphoryl lipid A using the contractor’s proprietary VesiVax liposomal system.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
- Development of a VesiVax HIV Vaccine Formulation
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense